Videnskabelig årsrapport 2005 - Rigshospitalet

Finsencentret
Ph.d.-studerende
Charlotte Elberling Almasi
Line Visby Hansen
Thore Hillig
Martin Illemann Pedersen
Birgitte Rønø
Udenlandske gæsteforskere
Professor Ole Didrik Lærum
Andre forskere
Lektor Morten Johnsen
Cand.scient. Anna Juncker-Jensen
Ph.d. Jacob Larsen
Overlæge Helle Pappot
Studenterforskere
Stud.scient. Signe Ingvarsen
Stud.scient. Benedikte Jacobsen
Stud.scient. Magnus Kjærgaard
Stud.scient. Daniel Hagbøll Madsen
Stud.scient. Morten Grønbech Rasch
Øvrigt forskningspersonale
Mette Musfeldt Andersen
Jette Christiansen
Yvonne DeLotto
Lotte Frederiksen
Gitte Juhl Funch
Agnieszka Ingvorsen
Kirsten Lund Jakobsen
Charlotte Lønborg Jensen
Birthe Larsen
Anne Møller
Suzanne Krizmanic Møller
Ruth Fabritius Petersson
Anna Margrethe Poulsen
Katharina Hassing Stegmann
Martha Væggemose
Vigtigste satsningsområder
inden for forskningen
Eksperimentel cancerforskning med
henblik på klinisk anvendelse.
Ekstracellulær proteolyse ved cancer
invasion og metastasering.
Basale mekanismer og identifikation af
molekyler involveret i disse
processer, udviking af nye
diagnostiske og terapeutiske metoder.
Publikationer
Disputatser og ph.d.-afhandlinger
forsvaret i året
Autzen PU. Proteolysis in prostate cancer
and prostate involution (ph.d.-
afhandling). København. Eget forlag;
2005:1-87. Forsvaret den 7/11 2005
ved Københvans Universitet, Det
Sundhedsvidenskabelige Fakultet.
Pass, J. Generation and characterization
of murine monoclonal antibodies
against the murine receptor for
urokinase plasminogen activator
(ph.d.-afhandling). København. Eget
forlag; 2005:1-114. Forsvaret den
21/6 2005 ved Københvans
Universitet, Det
Sundhedsvidenskabelige Fakultet.
Videnskabelige artikler
A. Førsteforfatter fra
forskningsenheden
Almasi CE, Hoyer-Hansen G, Christensen
IJ, Dano K, Pappot H. Prognostic
impact of liberated domain I of the
urokinase plasminogen activator
receptor in squamous cell lung cancer
tissue. Lung Cancer 2005;48(3):349-
55.
Almholt K, Lund LR, Rygaard J, Nielsen
BS, Dano K, Romer J, et al. Reduced
metastasis of transgenic mammary
cancer in urokinase-deficient mice.
Int J Cancer 2005;113(4):525-32.
Dano K, Behrendt N, Hoyer-Hansen G,
Johnsen M, Lund LR, Ploug M, et al.
Plasminogen activation and cancer.
Thromb Haemost 2005;93(4):676-81.
Green KA, Lund LR. ECM degrading
proteases and tissue remodelling in
the mammary gland. Bioessays
2005;27(9):894-903.
Holten-Andersen MN, Hansen U, Brunner
N, Nielsen HJ, Illemann M, Nielsen
BS. Localization of tissue inhibitor of
metalloproteinases 1 (TIMP-1) in
human colorectal adenoma and
adenocarcinoma. Int J Cancer
2005;113(2):198-206.
Jorgensen TJ, Bache N, Roepstorff P,
Gardsvoll H, Ploug M. Collisional
Activation by MALDI Tandem Timeof-flight
Mass Spectrometry Induces
Intramolecular Migration of Amide
Hydrogens in Protonated Peptides.
Mol Cell Proteomics
2005;4(12):1910-9.
Jorgensen TJ, Gardsvoll H, Ploug M,
Roepstorff P. Intramolecular
migration of amide hydrogens in
protonated peptides upon collisional
activation. J Am Chem Soc
2005;127(8):2785-93.
Larsen MB, Stephens RW, Brunner N,
Nielsen HJ, Engelholm LH,
Christensen IJ, et al. Quantification
of tissue inhibitor of
metalloproteinases 2 in plasma from
healthy donors and cancer patients.
Scand J Immunol 2005;61(5):449-60.
Pappot H, Pedersen AN, Brunner N,
Christensen IJ. The complex between
urokinase (uPA) and its type-1
inhibitor (PAI-1) in pulmonary
adenocarcinoma: Relation to
prognosis. Lung Cancer 2006;51:193-
200.
Pedersen TX, Pennington CJ, Almholt K,
Christensen IJ, Nielsen BS, Edwards
DR, et al. Extracellular protease
mRNAs are predominantly expressed
in the stromal areas of microdissected
mouse breast carcinomas.
Carcinogenesis 2005;26(7):1233-40.
Riisbro R, Christensen IJ, Nielsen HJ,
Brunner N, Nilbert M, Fernebro E.
Preoperative plasma soluble
urokinase plasminogen activator
receptor as a prognostic marker in
rectal cancer patients. An EORTC-
Receptor and Biomarker Group
collaboration. Int J Biol Markers
2005;20(2):93-102.
Usher PA, Thomsen OF, Iversen P,
Johnsen M, Brunner N, Hoyer-
Hansen G, et al. Expression of
urokinase plasminogen activator, its
receptor and type-1 inhibitor in
malignant and benign prostate tissue.
Int J Cancer 2005;113(6):870-80.
B. Medforfatter fra forskningsenheden
Curino AC, Engelholm LH, Yamada SS,
Holmbeck K, Lund LR, Molinolo
AA, et al. Intracellular collagen
degradation mediated by
uPARAP/Endo180 is a major
pathway of extracellular matrix
turnover during malignancy. J Cell
Biol 2005;169(6):977-85.
List K, Szabo R, Molinolo A,
Sriuranpong V, Redeye V, Murdock
T, et al. Deregulated matriptase
causes ras-independent multistage
carcinogenesis and promotes rasmediated
malignant transformation.
Genes Dev 2005;19(16):1934-50.
Llinas P, Le Du MH, Gardsvoll H, Dano
K, Ploug M, Gilquin B, et al. Crystal
structure of the human urokinase
plasminogen activator receptor bound
to an antagonist peptide. EMBO J
2005;24(9):1655-63.
Maillard C, Jost M, Romer MU, Brunner
N, Houard X, Lejeune A, et al. Host
plasminogen activator inhibitor-1
promotes human skin carcinoma
progression in a stage-dependent
manner. Neoplasia 2005;7(1):57-66.
Ostrowski SR, Piironen T, Hoyer-Hansen
G, Gerstoft J, Pedersen BK, Ullum H.
High plasma levels of intact and
cleaved soluble urokinase receptor
reflect immune activation and are
independent predictors of mortality in
HIV-1-infected patients. J Acquir
Immune Defic Syndr 2005;39(1):23-
31.
Ostrowski SR, Plomgaard P, Fischer CP,
Steensberg AS, Moller K, Hoyer-
Hansen G, et al. Interleukin-6
infusion during human endotoxaemia
inhibits in vitro release of the
urokinase receptor from peripheral
blood mononuclear cells. Scand J
Immunol 2005;61(2):197-206.
Ostrowski SR, Ullum H, Goka BQ,
Hoyer-Hansen G, Obeng-Adjei G,
Pedersen BK, et al. Plasma
concentrations of soluble urokinasetype
plasminogen activator receptor
are increased in patients with malaria
and are associated with a poor
clinical or a fatal outcome. J Infect
Dis 2005;191(8):1331-41.
Ostrowski SR, Piironen T, Hoyer-Hansen
G, Gerstoft J, Pedersen BK, Ullum H.
Reduced release of intact and cleaved
urokinase receptor in stimulated
whole-blood cultures from human
immunodeficiency virus-1-infected
patients. Scand J Immunol
2005;61(4):347-56.
Patenter
Lund LR, Danø K, Stephens R, Brünner
N, Solberg H, Holst-Hansen C
Nielsen JR. Inhibition of invasive
remodelling. European Patent no. EP
0942746. Approved 16.03.2005.
Ploug M, Østergaard S, Holst-Hansen C,
Stephens R, Danø K, Holm A.
Oligomeric peptide uPAR
antagonists. US Patent no.
09/743,329. Approved 23.09.2005.
28 Videnskabelig årsrappport